{
  "trial_id": "NCT00116779",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, baseline testosterone level, ECOG score, PSA value, history of prostate cancer treatment, history of other cancers, serum ALT level, serum total bilirubin level, presence of hepatic disease, presence of other clinically significant laboratory abnormalities, presence of clinically significant disorders, history of excessive alcohol or drug abuse, mental capacity, language proficiency, prior participation in investigational drug studies.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Serum Prostate-Specific Antigen",
          "PSA value"
        ],
        [
          "Serum Testosterone level",
          "baseline testosterone level"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Race (NIH/OMB)",
        "Curative Intent",
        "Participant Counts by Gleason Score",
        "The Number of Participants at Each Stage of Prostate Cancer",
        "Body Mass Index",
        "Days Since Diagnosis of Prostate Cancer",
        "Weight"
      ],
      "remaining_candidate_features": [
        "ECOG score",
        "history of prostate cancer treatment",
        "history of other cancers",
        "serum ALT level",
        "serum total bilirubin level",
        "presence of hepatic disease",
        "presence of other clinically significant laboratory abnormalities",
        "presence of clinically significant disorders",
        "history of excessive alcohol or drug abuse",
        "mental capacity",
        "language proficiency",
        "prior participation in investigational drug studies."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity, Customized, Region of Enrollment, Baseline testosterone level, PSA value, ECOG score, History of prostate cancer treatment, Serum ALT level, Serum total bilirubin level,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Serum Prostate-Specific Antigen",
          "PSA value"
        ],
        [
          "Serum Testosterone level",
          "Baseline testosterone level"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Curative Intent",
        "Participant Counts by Gleason Score",
        "The Number of Participants at Each Stage of Prostate Cancer",
        "Body Mass Index",
        "Days Since Diagnosis of Prostate Cancer",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Region of Enrollment",
        "ECOG score",
        "History of prostate cancer treatment",
        "Serum ALT level",
        "Serum total bilirubin level"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Male, Race/Ethnicity Not Collected, Region of Enrollment, Prostate Specific Antigen (PSA), Eastern Co-operative Oncology Group (ECOG) score, Testosterone level, Body Mass Index (BMI)",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Male",
          "Sex: Male"
        ],
        [
          "Serum Prostate-Specific Antigen",
          "Prostate Specific Antigen (PSA)"
        ],
        [
          "Serum Testosterone level",
          "Testosterone level"
        ],
        [
          "Body Mass Index",
          "Body Mass Index (BMI)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Race (NIH/OMB)",
        "Curative Intent",
        "Participant Counts by Gleason Score",
        "The Number of Participants at Each Stage of Prostate Cancer",
        "Days Since Diagnosis of Prostate Cancer",
        "Weight"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity Not Collected",
        "Region of Enrollment",
        "Eastern Co-operative Oncology Group (ECOG) score"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, ECOG score, PSA value, testosterone level, histological stage of prostate cancer, prior treatment (radical prostatectomy or radiotherapy), prior hormonal therapy, presence of metastases, liver function tests (ALT, bilirubin), medical history (asthma, anaphylactic reactions, angioedema, angioneurotic edema, Quincke's Edema, other cancer), concomitant medications.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Curative Intent",
          "prior treatment (radical prostatectomy or radiotherapy)"
        ],
        [
          "Serum Prostate-Specific Antigen",
          "PSA value"
        ],
        [
          "Serum Testosterone level",
          "testosterone level"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Sex: Female",
        "Male",
        "Race (NIH/OMB)",
        "Participant Counts by Gleason Score",
        "The Number of Participants at Each Stage of Prostate Cancer",
        "Body Mass Index",
        "Days Since Diagnosis of Prostate Cancer",
        "Weight"
      ],
      "remaining_candidate_features": [
        "ECOG score",
        "histological stage of prostate cancer",
        "prior hormonal therapy",
        "presence of metastases",
        "liver function tests (ALT, bilirubin)",
        "medical history (asthma, anaphylactic reactions, angioedema, angioneurotic edema, Quincke's Edema, other cancer)",
        "concomitant medications"
      ]
    }
  }
}